Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors
Completed
San Antonio Cancer Institute
Phase 1
1997-09-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with pemetrexed
disodium and irinotecan in treating patients who have metastatic solid tumors.
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
Completed
National Cancer Institute (NCI)
Phase 3
1999-11-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known if cisplatin is more effective with or without
pemetrexed disodium for malignant mesothelioma of the pleura.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without
pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that
cannot be removed by surgery.
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
Completed
Memorial Sloan Kettering Cancer Center
Phase 3
1999-11-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known if cisplatin is more effective with or without
pemetrexed disodium for malignant mesothelioma of the pleura.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without
pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that
cannot be removed by surgery.
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2000-12-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in
treating women who have metastatic breast cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
